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The dynamic structure of the granuloma serves to protect the body from microbiological
challenge. This organized aggregate of immune cells seeks to contain this challenge and
protect against dissemination, giving host immune cells a chance to eradicate the threat.
A number of systemic diseases are characterized by this specialized inflammatory process
and granulomas have been shown to develop at multiple body sites and in various tissues.
Central to this process is the macrophage and the arms of the innate immune response.
This review seeks to explore how the innate immune response drives this inflammatory
process in a contrast of diseases, particularly those with a component of immunodefi-
ciency. By understanding the genes and inflammatory mechanisms behind this specialized
immune response, will guide research in the development of novel therapeutics to combat
granulomatous diseases.
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INTRODUCTION
The innate immune system plays a central role in driving inflam-
mation and protecting the body from invading microorganisms.
This first line of defense is made up of white blood cells, secretory
molecules, and proteins which form an anatomical barrier to infec-
tion. Components of the innate immune system are important for
orchestrating granuloma formation in response to microbial and
foreign body challenge. This specialized inflammatory process can
occur throughout the body, varying in size, organization, and com-
position of innate immune cells involved. The ultimate function
of the granuloma is to contain and eradicate microorganisms or
chronic irritants that are resistant to elimination through the nor-
mal immune response. This process is finely balanced between
host protection and localized collateral damage to normal tissue
and potential loss of function.
An emerging concept that this specialized inflammatory
process is in fact a last resort when other immune protective
processes have failed is slowly becoming recognized. A number
of immunodeficiency disorders hereditary and acquired, present
with granulomatous inflammation at a variety of body sites. Gran-
uloma formation in patients with these disorders often has an
infective prequel. Failure to clear the infective organism results in
persistence and subsequent granuloma formation to try to contain
the infection. The aim of this review is to explore the role of the
innate immune system and its aberrant disorders in the formation
of the granuloma.
GRANULOMA FORMATION AND ROLE IN IMMUNODEFENSE
A granuloma is a collection of inflammatory cells, predominantly
mature macrophages that form an aggregate in response to an
antigen. This antigen can include invading bacteria, fungi, for-
eign bodies, and immune complexes (James, 2000; Schappi et al.,
2008; Ramakrishnan, 2012). The purpose of the granuloma is to
isolate this antigen from the body and to facilitate its eradication.
This crucial immune reaction serves to protect the body from
dissemination of the antigen, this being especially important in
the case of mycobacterial infections. Immune defects, in partic-
ular ones that specifically affect the innate immune system have
been shown to result in poor granuloma formation. Deficiency in
tumor necrosing factor alpha (TNFα), Interleukin 12 (IL-12), or
interferon gamma (IFNγ) also result in poor granuloma formation
(Ramakrishnan, 2012).
On initiation of the granulomatous response, antigen pre-
senting cells encountering an antigen release a cocktail of pro-
inflammatory cytokines and chemoattractants. This recruits neu-
trophils from the circulation into the infected area and these in
turn release additional cytokines to attract and activate monocytes.
Under normal circumstances the recruited neutrophils eliminate
the infective agent through the process of phagocytosis and diges-
tion within the phagocytic vacuole (Segal, 2005). When the infec-
tive agent is resistant to neutrophil clearance macrophages engulf
the antigen. Upon internalization, macrophages secrete additional
pro-inflammatory mediators and attempt to digest the foreign
body in order to present antigen derived peptides and lipids via
MHC class II and CD1 molecules to T cells, natural killer T cells
(NKT cells), and natural killer cells (NK cells). IFNγ secreted
by NK cells, NKT cells, and T cells, activates dendritic cells. The
dendritic cells in turn release copious amounts of TNFα to fur-
ther promote the influx of immune cells to the area, creating a
specialized microenvironment to deal with the foreign antigen
(Figure 1A). Upon internalization of the antigen, macrophages
secrete additional pro-inflammatory mediators and attempt to
digest the foreign body in order to present antigen derived peptides
and lipids via MHC class II and CD1 molecules to T antigen. The
dendritic cells also migrate to the local lymph nodes to present the
antigen to naïve CD4 cells. On secretion of IL-12 by dendritic cells,
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these naïve cells differentiate into T-helper 1 (Th1) cells, which
secrete IL-2 to promote their survival and expand their population.
Activated Th1 cells enter the circulation and are attracted into the
granuloma through the high levels of chemokines and adhesion
molecules present on the macrovascular endothelial cells. They
move about the granuloma using the macrophages as a scaffold to
crawl over (Egen et al., 2008), the granuloma resembles a fluid bag
rather than a “walled off” solid structure with cells freely moving
within in it (Savill and Fadok, 2000; Taylor et al., 2008).
Persistence of the antigen past this point leads to further
chronicity of the inflammation and a mature granuloma. Complex
cross talk between the individual immune cells and the surround-
ing epithelium via the production of high levels of TNFα and IFNγ
leads to further maturation of macrophages. These macrophages
become multinucleate giant cells, with increased phagocytosis and
bacterial digestion capabilities. This is all aimed at trying to erad-
icate the antigen. After a number of weeks, these cells become
terminally differentiated into epithelioid macrophages which con-
tain large number of lysosomes, mitochondria, and are engaged in
continued endocytic activity. Well-developed pseudopodia, allows
for close interdigitation and a tightly packed aggregation of these
enlarged cells. Finally, fibrosis occurs.
RELATION TO HUMAN DISEASE
A plethora of diseases in humans feature granulomatous inflam-
mation including infective, neoplastic, vasculitic immunodefi-
ciency states, and inflammopathies (Table 1). The rate of turnover
of macrophages is key to the histological presentation of the gran-
uloma. A highly toxic stimulus will result in macrophage death,
such as seen in epithelioid granulomas. Examples of this are gran-
ulomas seen in tuberculosis and cat’s scratch disease. This results
in constant influx of new macrophages to replace the dead cells.
Whereas, an inert stimulus will result in a granuloma with low
turnover of macrophages.
INFECTIVE GRANULOMAS
As the most frequent cause of granulomas, Mycobacterium tuber-
culosis has killed more people throughout history than any other
infective disease (Lawn and Zumla, 2011). This suggests that tuber-
culous granulomas are not always efficient at eradicating this
pathogen. Tuberculosis infections often manifest themselves in
immunodeficiency states, suggesting that the innate immune sys-
tem is key to maintaining effective granuloma formation and
eradication of M. tuberculosis. Recent research shows that this
intracellular pathogen can exploit the innate immune system in
the early stages of granuloma formation to facilitate its persistence
and potential systemic dissemination. On inhalation M. tubercu-
losis is rapidly phagocytosed by resident lung macrophages. They
quickly replicate inside the macrophages and are transported to the
surrounding tissues inside these cells. To try and prevent further
dissemination and to ultimately exterminate the microorganism,
granuloma formation is initiated.
The importance of the innate immune system in tuber-
culous granuloma formation is highlighted by the zebrafish
model. Zebrafish larvae do not have an adaptive immune sys-
tem, yet still form highly organized granulomas. Imaging studies
inside zebrafish have shown macrophages arriving at a forming
Table 1 |Table of granulomatous disorders.
Granulomatous disease
I. INFECTIONS
• Fungi
◦ Histoplasma
◦ Coccidioides
◦ Blastomyces
◦ Sporothrix
◦ Aspergillus
◦ Cryptococcus
• Protozoa
◦Toxoplasma
◦ Leishmania
•Metazoa
◦ Schistosoma
• Spirochetes
◦T. palladium
◦T. carateum
◦T. perunue
•Mycobacteria
◦M. tuberculosis
◦M. kansasii
◦M. leprae
◦M. marinum
◦M. avian
◦ BCG vaccine
• Bacteria
◦ Brucella
◦Yersinia
2. VASCULITIS
•Wegener’s granulomatosis
• Necrotizing sarcoidal
• Churg–Strauss
• Broncho centric
• Polyarteritis nodosa
• Lymphomatoid
• Giant cell arteritis
• Systemic lupus erythematosus
• Beçhets disease
3. IMMUNOLOGICAL ABERRATIONS
• Crohn’s disease
• Orofacial granulomatosis
• Sarcoidosis
• Langerhan’s granulomatosis
• Hepatic granulomatous disease
• Primary biliary cirrhosis
• Blau’s syndrome
• Peyronie’s disease
• Immune complex disease
• Histiocytosis X
4. CHEMICALS
• Beryllium
• Zirconium
• Silica
(Continued)
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Table 1 | Continued
Granulomatous disease
• Starch
•Talc
5. NEOPLASIA
• Carcinoma
• Reticulosis
• Pinealoma
• Dysgerminoma
• Seminoma
• Reticulum cell sarcoma
•Malignant nasal granuloma
6. MISCELLANEOUS INFECTIONS
•Whipple’s disease
• Cat scratch
• Lymphogranuloma
• Kikuchi
• Buruli ulcer
8. HYPERSENSITIVITY PNEUMONITIS
• Farmers’ lung
• Bird fanciers’
• Suberosis (cork dust)
•Mushroom workers’
•Maple bark strippers’
• Bagassosis
• Paprika splitters’
• Spatlese lung
• Coffee bean
10. IMMUNODEFICIENCIES
• Chediak–Higashi
• Ataxia telangiectasia
• NBS
• RAG deficiency
• Artemis deficiency
• Jak3 deficiency
• HLA class I deficiency (TAP deficiency)
• Griscelli syndrome
• Common variable immunodeficiency
• Kabuki syndrome
• HIV (bacillary angiomatosis)
• CGD
• Hermansky–Pudlak
• Felty’s syndrome
• Common variable ID (CVID)
• Cartilage-hair hypoplasia SCID
granuloma moving fluidly and rapidly within it (Davis et al., 2002).
On encountering a dying macrophage, the incoming macrophage
phagocytoses the dying cell and is subsequently infected with
M. tuberculosis. The chemotaxis of macrophages into the gran-
uloma is orchestrated by the M. tuberculosis RD-1 virulence locus,
which encodes a type VII secretion system ESX-1 and its sub-
strate ESAT-6. Strains lacking RD-1 have reduced macrophage
ingress into what is a poorly formed granuloma and an atten-
uated infection. This is suggestive that M. tuberculosis utilizes
granuloma formation as a protective mechanism to ensure its sur-
vival. TNFα was thought to play a central role in tuberculous
granuloma formation as TNFα deficient mice showed poor gran-
uloma formation. Studies in zebrafish have now shown this may
not be the case as granulomas still form in the absence of TNFα,
but are not maintained. Due to a lack of TNFα, macrophages
are unable to effectively kill and digest the ingested Mycobacteria.
The structure of the granuloma is lost in TNFα deficient animals
when these overburdened macrophages die (Clay et al., 2008). The
importance of TNFα in granuloma integrity is clearly illustrated
in the reactivation of latent M. tuberculosis in humans undergoing
anti-TNFα antibody therapy. Reactivation of infection is results
from an impairment in bacterial containment due to the loss of
a fully functional granuloma and reduced CD8+ T cell immu-
nity during therapy (Miller and Ernst, 2009). Neutrophils also
play a central role in the tuberculous granuloma with peak levels
at 3 weeks after inoculation (Wolf et al., 2007). Failure of nor-
mal macrophage functioning in granuloma results in an increase
of these cells in the granuloma. The consequence of impaired
macrophage microbiocidal activity is the onset of necrosis which
attracts neutrophils into the granuloma in response (Cooper et al.,
1993; MacMicking et al., 2003). Increased neutrophil ingress has
been shown to herald increased pathology in M. tuberculosis infec-
tions. Deficiency in caspase recruitment domain-containing pro-
tein 9 (CARD9) results in neutrophil-rich granulomas (Dorhoi
et al., 2010; Redford et al., 2010). CARD9 mediates signals from
so called pattern-recognition receptors such as toll-like receptors
(TLRs), NOD-like receptors (NLRs), and dectin-1activate down-
stream pathways, including NF-κB. This subsequently induces the
release of cytokines to stimulate/regulate the innate and adaptive
immune responses. One such cytokine is the immunomodulator
IL-10, essential for downregulation of IL-23 signaling and subse-
quent IL17 production. IL-17 is secreted by Th-17 and γδ T cells
and leads to mass neutrophil influx into the granuloma (Lock-
hart et al., 2006). This is supported by the fact peak neutrophil
influx occurs around day 21 and coincides with the activation
of the adaptive immune response. In schistosome infection how-
ever, a Th-2 dominant response is mounted, absence of the Th-2
cytokine IL-4 results in increased hepatocyte damage, driven by
excessive proinflammatory mediator secretion. This suggests the
Th-2 response is protective for excessive immune stimulation and
response to schistosome eggs (Pearce et al., 2004). Dorhoi et al.
showed that CARD9 knockout mice failed to secrete IL-10 and
produced neutrophilic granulomas due to increased IL-17 levels.
These mice subsequently died from an aberrant excessive inflam-
matory response that resulted in the dissemination of the infection
(Dorhoi et al., 2010). A role for CARD9 in the development of
Crohn’s disease has also been highlighted through its identifica-
tion in genome wide association studies (GWAS) (Franke et al.,
2010).
COMPLEX DISEASE OF ABERRANT IMMUNE FUNCTION
Sarcoidosis
Sarcoidosis is a systemic disease affecting multiple systems, but
particularly barrier tissues such as the lungs, eyes, and skin (Rastogi
et al., 2011). Current research has suggested that both environmen-
tal and genetic factors play a role in this complex disease. A GWAS
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conducted using 499 German individuals with sarcoidosis and
490 controls, detected an association to the ANXA11 (annexin 11)
gene on chromosome 10q22.3 (Hofmann et al., 2008). This pro-
tein has been implicated in a number functions including vesicle
trafficking and apoptosis (Gerke and Moss, 2002). It is thought
that the prevention of propagation of granulomatous inflamma-
tion is controlled by apoptotic mechanisms of inflammatory cells.
It facilitates calcium dependant interaction with ALG-2 a glycosyl-
transferase, which is necessary for caspase cell-induced death (Rao
et al., 2004). It is therefore possible if annexin 11 regulated apop-
totic mechanisms are affected because of this mutation, activated
inflammatory cells survive and drive the granulomatous response
further to cause wide spread disease.
High levels of TNFα and IL-12 in the serum of patients
with the disease has been shown and also increased production
of these cytokines by peripheral blood monocytes and alveo-
lar macrophages (Prior et al., 1996). Macrophages are important
defense cells in the lungs and are critical for initiating an inflamma-
tory response on stimulation by inhaled microbes and toxins. This
is facilitated through recognition of pathogen-associated molecu-
lar patterns (PAMPS) through pattern-recognition receptors such
TLRs and NLRs. Rastogi et al. (2011) have shown that the high
cytokine levels detected in patients with sarcoidosis is down to
stimulation of alveolar macrophages with TLR4 and NOD1 ago-
nists. This in turn leads to sustained p38 phosphorylation and
cytokine production, particularly increased transcription of IL-
12, TNFα, and IL-1 (Dong et al., 2002; Inoue et al., 2006). TNFα
maintains the integrity and maintenance of the granuloma and
limits the influx of inflammatory cells to the granuloma to prevent
escalation of the inflammatory process.
Paradoxically, anti-TNFα induced sarcoidosis has also been
reported in the literature, mainly affecting the lungs, parotid, and
skin (Massara et al., 2010). After withdrawal of anti-TNFα therapy
the condition resolves, it is thought that the cytokine imbalance
experienced on prolonged TNFα blockade precludes the disease.
Corticosteroid therapy has also been shown to be detrimental in
recent onset disease (Reich, 2003, 2012).
Dendritic cells play a central role in granuloma formation by
directly recruiting immune cells via TNFα secretion and indirectly
through the activation of T cells via presentation of antigen in the
surrounding lymph nodes. Patients with sarcoidosis have shown
to present with a deficit in delayed type hypersensitivity reac-
tions through impairment of dendritic cell functioning (Mathew
et al., 2008). The same group also showed that sarcoid patients
have comparable levels of circulating dendritic cells to that of
healthy controls, but these dendritic cells display anergy to micro-
bial challenge, despite the presence of upregulatied costimulatory
and maturation markers (Mathew et al., 2008). This dysfunction is
mild and therefore does not predispose these individuals to severe
microbial infections as seen with those with primary immunodefi-
ciencies. The same group also demonstrated a correlation between
the degree of dendritic cell dysfunction and severity of pulmonary
disease.
It has also been suggested that Tuberculosis and sarcoidosis
are different spectrums of the same disease (Gupta et al., 2012).
The histological and clinical similarities of both diseases could
point to the fact that sarcoidosis is immune hypersensitivity to
mycobacterial antigens, whilst in patients with tuberculosis; an
underactive immune process.
Primary biliary cirrhosis
Activation of the innate immune system in this organ specific
autoimmune disorder is thought to be key in the early stages
of this disease as seen by eosinophilic infiltrations and elevated
IgM (Berg, 2011). Biliary epithelial cells express a number of
pattern-recognition receptors and are the first line of defense
against foreign invaders in the liver. They are repeatedly exposed to
PAMPS and through TLR and NLR signaling eventually undergo
apoptosis. It is hypothesized that increased activation of apoptosis
within these cells is via loss or down regulation of Bcl-2 and this
in turn plays a major role in the disease process (Garchon et al.,
1994). Poor clearance of these apoptotic and damaged cells by
macrophages leads to their persistence and subsequent stimulation
of the adaptive immune response and the tissue damage and gran-
uloma formation that ensues, which is thought to be the primary
mechanism driving the disease process. Particularly, exposure of
mitochondrial membrane proteins leads to production of antim-
itochondrial autoantibodies (AMAs) which are a feature of the
disease. This can lead to development of concomitant autoim-
mune disorders (Watt et al., 2004). The balance between bile duct
proliferation and damage is the hallmark of this disease process
which affects biliary epithelial cells.
GRANULOMA FORMATION IN IMMUNODEFICIENCY STATES
A number of immunodeficiency disorders present with granu-
lomatous inflammation, including hereditary immunodeficiency
states such as common variable immunodeficiency and chronic
granulomatous disease (CGD). Diseases which present with gran-
ulomas such as Crohn’s disease have also recently been shown to
have an element of immunodeficiency (Rahman et al., 2008).
Crohn’s disease
One of the most common causes of granuloma formation in the
gastrointestinal tract is the inflammatory bowel disorder; Crohn’s
disease. Granulomas in Crohn’s patients can occur anywhere along
the gastrointestinal tract from the mouth to the rectum. A com-
plex interplay between the microbial contents, estimated to be 1014
bacteria, the epithelium and immune components drives this dis-
ease process. The gastrointestinal tract has a multi-layered defense
system which consists of physical barriers, anti-bacterial mole-
cules, and a range of leukocytes. Epithelial goblet cells secrete
mucins, which act as a barrier to invading bacteria, whilst paneth
cells secrete defensins which are primitive microbicidal peptides.
Innate immune cells such as macrophages and dendritic cells
are present in the lamina propria for immunosurveillance. It is
though that a breakdown in this complex homeostasis between
the gut microflora and host defense mechanisms is the precipitat-
ing cause to Crohn’s (Marks and Segal, 2008). A major hypothesis
centers on the impaired handing and clearance of luminal content
which gains access into the bowel wall (Sewell et al., 2009). The
precise mechanisms responsible for this impaired innate immune
response are still not fully understood. Recent GWAS (Barrett et al.,
2008; Franke et al., 2010) have identified over 70 genetic polymor-
phisms associated with Crohn’s and this number is expected to
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increase over the next few years (Lees et al., 2011). Many of these
loci have been linked to genes involved in bacterial recognition,
innate immunity, and autophagy. Interestingly a large proportion
of the genes identified are also associated with other immune
conditions illustrating common pathological processes in quite
different phenotypes (Lees et al., 2011).
Genome wide association studies have identified several genes
associated with autophagy (ATG16L1, IRGM, LRRK2, ULK1, and
NOD2) (Levine and Deretic, 2007). NOD2 the most strongly
associated gene with Crohn’s disease is responsible for pro-
inflammatory cytokine release and autophagy induction (Hugot
et al., 2001; Ogura et al., 2001; Travassos et al., 2010). Expressed
predominantly by macrophages, NOD2 recruits another Crohn’s
associated protein ATG16L1 to the cell membrane and acts
as a sensor for bacterial peptidoglycan smallest subunit N -
acetylmuramyl-L-alanyl-D-isoglutamine (MDP) and activating
autophagy machinery (Torok et al., 2009). Numerous genetic
studies have identified three NOD2 polymorphisms rs2066844
(R702W), rs2066845 (G908R), and rs2066847 (1007fs) as being
associated with increased susceptibility for Crohn’s disease, com-
mon to all three is a loss in MDP sensitivity and an inability to
activated downstream targets, thus inducing an immunodeficiency
in carriers (Burton et al., 2007; Franke et al., 2010). ATG16L is
expressed in the epithelial cells of the intestine, in leukocytes, and
the spleen (Fujita et al., 2008). Studies have shown that muta-
tion of ATG16L (T300A) has an association with the formation
of ileal Crohn’s disease (Prescott et al., 2007; Sventoraityte et al.,
2010).
The mechanism of autophagy within the gut and has a number
of functions to maintain homeostasis. The first of these is intracel-
lular defense against microorganisms via the process of xenophagy
(Gardet and Xavier, 2012). This is thought to be important in the
tight control of the innate immune response against commensals
gut organisms. If this process is affected and bacterial handling
impaired, this can lead to an inappropriate host inflammatory
response against commensal organisms. Some of these genes
(IRGM, NOD2, LRRK2) are also associated with infective gran-
ulomatous disorders, thus suggesting Crohn’s patients may have
altered control of mycobacterial infections (Intemann et al., 2009;
Kumar et al., 2010). Autophagy proteins have also been shown
to be involved in the regulation of the inflammasome through
defects in mitochondrial autophagy leading to increase reactive
oxygen species and loss of regulation of inflammasome path-
ways, particularly the pro-IL-1β pathway. Plantinga et al. (2011)
demonstrated that mutation in ATG16L results in monocytes with
increased IL1β secretion on stimulation with MDP. Dendritic cells
also rely on autophagy for antigen presentation (Schmid et al.,
2007). Recent evidence has suggested that defects in autophagy
proteins may destabilize the immune cross talk between dendritic
cells and T cells leading to an increased inflammatory response
(Wildenberg et al., 2012). It can be assumed that this could add
to the collateral damage caused by the immune system within
the gut. The last function of autophagy is maintenance of secre-
tory granules in paneth cells, which have a role in innate immune
defense in the gut. NOD2 and ATG16L are expressed by paneth
cells, and through NLR and TLR signaling pathways these cells
release a cocktail of antimicrobial proteins, including lysozyme,
but principally they secrete alpha defensins. These hydrophobic
peptides are pore forming units that disrupt bacterial cell mem-
brane leading to lysis and death. The 1007fs mutation in NOD2
has been proven to decrease defensin expression and this is sup-
ported by the observation that patients with NOD2 mutations
have lower defensins titers in ileostomy fluid compared to controls
(Wehkamp et al., 2005; Van Limbergen et al., 2007). Lower levels of
these proteins could facilitate entry of bacteria into the epithelial
cells and a breach in the mucosal integrity. The T300A mutation
in ATG16L also results in a decrease in secretory granule number
within paneth cells. This loss of the mucosal barrier is the first step
in the suggested multistep pathogenesis of Crohn’s (Marks and
Segal, 2008). The next step involves reduction in bacterial killing
capacity and clearance by neutrophils (Figure 1B).
Neutrophils play a central role in bacterial clearance from the
gut and in the etiopathogenesis of Crohn’s. The importance of neu-
trophils in gut immunity becomes clear when you consider mono-
genic diseases that result in neutrophil dysfunction and the high
incidence in bowel inflammation in these patients. These diseases
are covered in more detail in the following section and a recent
review (Rahman et al., 2008). A profound defect in the recruit-
ment of neutrophils into tissues after stimulation with heat killed
Escherichia coli and the subsequent failure to adequately clear this
bacterial challenge has been identified in patients with Crohn’s
disease (Smith et al., 2009). The neutrophils themselves func-
tion normally, but impaired cytokine secretion from macrophages
results in their failure to accumulate in adequate numbers in the
tissues (Marks et al., 2006; Smith et al., 2009). The consequence
of this delayed recruitment results in bacteria remaining in the
tissue, macrophages engulf the remaining bacteria and fecal mat-
ter inciting an inflammatory response culminating in granuloma
formation. The defect is within the macrophage, specifically the
vesicular trafficking and secretion of cytokines. Gene transcription
and synthesis of TNFα was found to be normal in macrophages
of Crohn’s disease patients, but secreted levels were grossly atten-
uated as a result of defective intracellular trafficking (Smith et al.,
2009).
IL23R is another gene with several SNPs associated with Crohn’s
disease (Duerr et al., 2006) as well as members of the IL23 path-
way; Jak2 and STAT3 (Barrett et al., 2008). Secreted by activated
dendritic cells, macrophages and monocytes, IL23 induces the
developed of TH17cells and induces IL1, IL6, and TNFα from
macrophages and monocytes. Primary immunodeficiencies char-
acterized by mutations in IL23 pathway genes also present with
granulomatous inflammation (see Table 2).
All these disorders have defects with the innate immune
response and form granulomas in various tissues throughout
the body.
The association of genes in autophagy regulation, IL-23 path-
way, and defects in bacterial handling lends itself to the formation
of the hypothesis that Crohn’s results from a defect in the digestion
and removal of bacteria from the tissue. The remaining bacteria
are walled off in the tissue and a granuloma forms to restrict dis-
semination of any infective agents. The granuloma then secretes
pro-inflammatory cytokines and presents antigens to the adaptive
immune system resulting in T cell activation. This response dri-
ves a chronic inflammatory condition which is the hallmark of
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Table 2 | Immunodeficiency disorders that present with granulomatous inflammation.
Disease Gene Inheritance Granuloma location Reference
Hermansky–Pudlak
syndrome
HPS-1, HPS-3, 10q23.1-23.3 Autosomal recessive GI tract Schinella et al. (1980)
Chronic granulomatous
disease
NCF1, NCF2, CYBA, and CYBB X-linked or autosomal recessive Liver, mouth, skin, lungs,
urinary tract, GI tract
Segal et al. (1978)
Chediak–Higashi
disease
CHS1 (LYST ), 1q42-43 Autosomal recessive GI tract Ishii et al. (1987)
RAG deficiency RAG1 RAG2 genes Autosomal recessive Cutaneous, mucous
membranes, and internal
organs
Schuetz et al. (2008)
Artemis deficiency
(SCID-Athabascan)
DCLRE1C Autosomal recessive Cutaneous IJspeert et al. (2011)
Janus kinase 3 (Jak3)
deficiency
ILR2G Autosomal recessive form of
severe combined
immunodeficiency (SCID)
Cutaneous Gregoriou et al. (2008)
Griscelli syndrome RAB27a Autosomal recessive Cutaneous Eyer et al. (1998)
Common variable
immunodeficiency
(CVID)
ICOS,TNFRSF13B (encoding
TACI),TNFRSF13C (encoding
BAFF-R), and CD19.
Autosomal recessive and
dominant forms
Lung, liver, skin, heart, eyes,
gastrointestinal tract, and
splenic granulomas
Ardeniz and
Cunningham-Rundles
(2009)
Ataxia telangiectasia A-T mutated gene (11q22-23) Autosomal recessive Cutaneous granulomas Chiam et al. (2011)
Nijmegen breakage
syndrome (NBS)
nbs1(8q21) Autosomal recessive Cutaneous Yoo et al. (2008)
TAP deficiency/bare
lymphocyte syndrome
type 1 group 3 (BLS)
tap1 tap 2 genes Autosomal recessive Necrotizing cutaneous, gut
and lung granulomas
Moins-Teisserenc
et al. (1999), Zimmer
et al. (2005)
Wiskott–Aldrich
syndrome
WAS gene, on the
X-chromosome (Xp11.23-p11.22
X-linked recessive Cutaneous Sebire et al. (2003)
Hyper IgM CD40L gene long arm of the
X-chromosome (Xq26-27.2)
X-linked recessive (autosomal
recessive and dominant forms)
Cutaneous Gallerani et al. (2004)
Crohn’s disease and the focus of the majority of current therapeu-
tic agents. Future drug design could target the defective bacterial
clearance by boosting macrophage function and subsequently
reducing granuloma formation which may prove advantageous.
Monogenic disorders of neutrophil function
Although neutrophil defects do not appear to be the primary cause
of Crohn’s, disorders which result in low neutrophil numbers such
as cyclical neutropenia, disorders of bacterial digestion such as
CGD and disorders of impaired vesicle trafficking and expul-
sion (Chediak–Higashi and Hermansky–Pudlak syndromes), can
present with a Crohn’s-like gut. This includes granuloma forma-
tion in the lamina propria and ulceration. Approximately half of
all CGD patients develop bowel inflammation which is indis-
tinguishable from Crohn’s disease (Marks et al., 2009). These
observations support the important role of neutrophils in healthy
gut maintenance and a reduction of functioning in granuloma
formation.
Chronic granulomatous disease affects primarily males and
is a rare congenital disease that is either X-linked or autoso-
mal recessive (Holland, 2010). This disorder is characterized by
a defect in the superoxide generating NADPH oxidase system
in neutrophils which is necessary for killing microorganisms by
respiratory burst. The pathognomic feature of CGD is recur-
rent infections, particularly by catalase positive bacteria and fungi
(Martire et al., 2008). This impaired bacterial killing leads to
granuloma formation in a variety of organs including the liver,
gut, skin, and mouth (Levine et al., 2005). Defects of the pro-
teins which are responsible for governing the respiratory burst
to generate reactive oxygen species have been identified as the
cause of this condition (Dinauer et al., 1987; Volpp et al., 1988;
Clark et al., 1989). An unbalance in the expression of innate
immune receptors on neutrophils has also been shown to have
a causal role in CGD. Neutrophils in CGD patients show reduced
expression of TLR5, TLR9, and CD18, reduced TLR5 levels result-
ing in reduced activation by bacterial flagella. Lowered CD18
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expression results in impaired killing of Staphylococcus aureus.
Both TLR5 and TLR9 expression levels have been shown to cor-
relate with the severity of the disease, higher expression seen in
patients with higher residual NADPH oxidase and a less severe
phenotype (Rieber et al., 2012). Many CGD patients suffer from
concomitant autoinflammatory conditions such as systemic lupus
erythematosis and pulmonary fibrosis, potentially suggesting an
uncontrolled inflammatory response tipping toward hyperinflam-
mation (Winkelstein et al., 2000; Rieber et al., 2012). Upregulation
of several pro-inflammatory genes has been identified by microar-
ray analysis on activation of TLR2 or TLR4, which is independent
of NADPH oxidase activity (Kobayashi et al., 2004; Bylund et al.,
2007). In addition to the neutrophil the NADPH oxidase system
is utilized by the macrophage and defective immune responses
FIGURE 1 | Continued
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FIGURE 1 | (A) Diagram of a mature granuloma. After 3 weeks of
maturation, the granuloma is fully formed. Crosstalk between various cells
of the immune system leads to proliferation of lymphocytes,
predominantly T-helper cells. (a) Macrophages engulf the antigen and
secrete pro-inflammatory cytokines. They also present antigen derived
peptides and lipids via MHC class II and CD 1 molecules to T cells, natural
killer T cells (NKT cells), and natural killer cells (NK cells). (b) Thl cells
secrete IFNγ which activates dendritic cells. (c) Dendritic cells loaded with
antigen migrate to the local lymph nodes where they present to naive
CD4+T cells. (d) Within the lymph node, the dendritic cells secrete IL-12
which stimulates these naive cells to differentiate into Thl cells. These in
turn secrete IL2 to expand their population. (e) At the granuloma site,
activated dendritic cells secrete copious amounts of TNFα which activates
the endothelium, upregulating the number of adhesion molecules to allow
extravasation of Thl cells and monocytes. (f) Thl cells secrete IFNγ which
stimulates monocytes to differentiate into macrophages. (B)
Diagrammatic representation of the multistep pathogenesis of Crohn’s
disease. (1) Loss of integrity in the gut epithelium allows bacteria to leave
the lumen and enter the tissue of the gut. (2) Defective autophagy. (3)
Mutation of NOD2 leads to reduction in secretion of pro-inflammatory
cytokines including TNFα. (4) Defect in Neutrophil function (monogenic
diseases) or reduced chemotaxis (inherited or due to reduced TNFα
secretion). This leads to persistence of bacterium in the tissues. (5)
Mutational the IL23R on Thl7 cells leads to increased survival of these
cells and increased IL17 production. High levels of IL17 is associated with
increased bowel inflammation in Crohn’s. (6) Mutation of ATG16L (T300A)
leads to a excessive of production of IL-lβ. (7) Mutation in NOD2 leads to
reduced defensin production by intestinal Paneth cells.
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are also evident in CGD patients (Rahman et al., 2009). Impaired
macrophage function is also evident in CGD, with attenuated pro-
inflammatory cytokine and increased IL-10 secretion following
bacterial stimulation. The role this plays in the development of
granulomatous inflammation is still unclear.
AUTOINFLAMMATORY STATES
Blau syndrome is another immune disease which features granu-
loma formation. This rare autosomal dominant disorder can be
characterized by granulomatous polyarthritis, uveitis, macropapu-
lar skin lesions containing granulomas and cranial neuropathies.
Crohn’s-like disease occurs in 30% of patients (Geha et al., 2007). A
missense mutation in NOD2 drives this disease resulting in a gain
of function and periodic episodes of fever and inflammation clas-
sic of this disorder (Fritz et al., 2006). This is a direct opposite of
the loss of function seen in NOD2 associated with Crohn’s disease,
although both conditions result in granuloma formation. Mono-
cytes derived from patients with Blau syndrome after stimulation
with macrophage colony-stimulating factor had a greater ability to
form multinucleate giant cells compared to healthy controls (Yasui
et al., 2010). Macrophages also displayed increased adherence and
expression of inter-cellular adhesion molecule-1 (ICAM1), which
could suggest an increase in ability for macrophage fusion and
giant cell generation.
Blau syndrome granulomas are immunohistochemically dis-
tinct from those of Sarcoidosis or Crohn’s. A thick halo of lympho-
cytes, particularly Th17 cells surrounds the macrophages (Rose
et al., 2011). Another observation in Blau syndrome granulo-
mas is the phagocytosis of lymphocytes which can be found
with their cytoplasms intact within the multinucleate giant cells
of the granuloma. The gain of function of NOD2 and its role
in autophagy could explain this phenomenon. Granulomas in
patients with Crohn’s disease there is an absence of this halo of
lymphocytes and an increase in neutrophils and sclerosis in the
surrounding tissue (Janssen et al., 2012).
SUMMARY
Our understanding of the complex mechanisms that underlie
granuloma formation and maintenance is growing, particularly
the role of the innate immune system. Genetic studies have iden-
tified that many diseases of immune aberration and granuloma
formation share common genetic backgrounds (Lees et al., 2011).
Although, many of these diseases have multiple causal mutations
associated with the disease process. Understanding the genetic
overlap between these diseases is key to elucidating common path-
ways and mechanisms for the disease process in this specialized
inflammatory response.
The key to finding new treatment strategies to combat gran-
ulomatous disorders lies with understanding the genetic and
immunological background to immunodeficiency diseases that
result in granuloma formation. Insight into the complex immune
signaling pathways which drive these diseases will hopefully in
turn highlight appropriate targets for novel therapeutic ther-
apies. The fact that granuloma formation is associated with
immunodeficiency states and also can be initiated in some dis-
eases by immunomodulatory drugs highlights the need for cau-
tion in prescribing immunosuppressants to treat granulomatous
diseases.
ACKNOWLEDGMENTS
HJP is funded by the small grants scheme from the Dental Faculty
of the Royal College of Surgeons of England.
REFERENCES
Ardeniz, O., and Cunningham-Rundles,
C. (2009). Granulomatous disease
in common variable immunodefi-
ciency. Clin. Immunol. 133, 198–207.
Barrett, J. C., Hansoul, S., Nicolae,
D. L., Cho, J. H., Duerr, R. H.,
Rioux, J. D., et al. (2008). Genome-
wide association defines more than
30 distinct susceptibility loci for
Crohn’s disease. Nat. Genet. 40,
955–962.
Berg, P. A. (2011). The role of the innate
immune recognition system in the
pathogenesis of primary biliary cir-
rhosis: a conceptual view. Liver Int.
31, 920–931.
Burton, P. R., Clayton, D. G., Cardon, L.
R., Craddock, N., Deloukas, P., Dun-
canson, A., et al. (2007). Genome-
wide association study of 14,000
cases of seven common diseases and
3,000 shared controls. Nature 447,
661–678.
Bylund, J., MacDonald, K. L., Brown, K.
L., Mydel, P., Collins, L. V., Hancock,
R. E. W., et al. (2007). Enhanced
inflammatory responses of chronic
granulomatous disease leukocytes
involve ROS-independent activation
of NF-kappa B. Eur. J. Immunol. 37,
1087–1096.
Chiam, L. Y. T., Verhagen, M. M.
M., Haraldsson, A., Wulffraat, N.,
Driessen, G. J., Netea, M. G., et al.
(2011). Cutaneous granulomas
in ataxia telangiectasia and other
primary immunodeficiencies:
reflection of inappropriate immune
regulation? Dermatology 223,
13–19.
Clark, R. A., Malech, H. L., Gallin, J.
I., Nunoi, H., Volpp, B. D., Pear-
son, D. W., et al. (1989). Genetic-
variants of chronic granulomatous-
disease – prevalence of deficiencies
of 2 cytosolic components of the
NADPH oxidase system. N. Engl. J.
Med. 321, 647–652.
Clay, H., Volkman, H. E., and
Ramakrishnan, L. (2008). Tumor
necrosis factor signaling mediates
resistance to mycobacteria by
inhibiting bacterial growth and
macrophage death. Immunity 29,
283–294.
Cooper, A. M., Dalton, D. K., Stewart,
T. A., Griffin, J. P., Russell, D. G.,
and Orme, I. M. (1993). Dissem-
inated tuberculosis in interferon-
gamma gene-disrupted mice. J. Exp.
Med. 178, 2243–2247.
Davis, J. M., Clay, H., Lewis, J.
L., Ghori, N., Herbomel, P., and
Ramakrishnan, L. (2002). Real-time
visualization of mycobacterium-
macrophage interactions leading to
initiation of granuloma formation
in zebrafish embryos. Immunity 17,
693–702.
Dinauer, M. C., Orkin, S. H., Brown,
R., Jesaitis, A. J., and Parkos,
C. A. (1987). The glycoprotein
encoded by the X-linked chronic
granulomatous-disease locus is
a component of the neutrophil
cytochrome-B complex. Nature 327,
717–720.
Dong, C., Davis, R. J., and Flavell, R. A.
(2002). MAP kinases in the immune
response. Annu. Rev. Immunol. 20,
55–72.
Dorhoi, A., Desel, C., Yeremeev,
V., Pradl, L., Brinkmann, V.,
Mollenkopf, H. J., et al. (2010).
The adaptor molecule CARD9
is essential for tuberculosis
control. J. Exp. Med. 207,
777–792.
Duerr, R. H., Taylor, K. D., Brant, S. R.,
Rioux, J. D., Silverberg, M. S., Daly,
M. J., et al. (2006). A genome-wide
association study identifies IL23R as
an inflammatory bowel disease gene.
Science 314, 1461–1463.
Egen, J. G., Rothfuchs, A. G., Feng, C. G.,
Winter, N., Sher, A., and Germain, R.
N. (2008). Macrophage and T cell
dynamics during the development
and disintegration of mycobac-
terial granulomas. Immunity 28,
271–284.
Eyer, D., Petiau, P., Finck, S., Heid,
E., Grosshans, E., and Lutz, P.
(1998). Cutaneous granuloma-
tous lesions in a patient with
Griscelli syndrome. Annales de
Dermatologie et de Venereologie 125,
727–728.
Franke, A., McGovern, D. P. B., Bar-
rett, J. C., Wang, K., Radford-
Smith, G. L., Ahmad, T., et al.
(2010). Genome-wide meta-analysis
increases to 71 the number of con-
firmed Crohn’s disease susceptibility
loci. Nat. Genet. 42, 1118.
www.frontiersin.org May 2013 | Volume 4 | Article 120 | 9
Petersen and Smith innate immune system in granulomas
Fritz, J. H., Ferrero, R. L., Philpott, D. J.,
and Girardin, S. E. (2006). Nod-like
proteins in immunity, inflamma-
tion and disease. Nat. Immunol. 7,
1250–1257.
Fujita, N., Itoh, T., Omori, H., Fukuda,
M., Noda, T., and Yoshimori, T.
(2008). The Atg16L complex spec-
ifies the site of LC3 lipidation for
membrane biogenesis in autophagy.
Mol. Biol. Cell 19, 2092–2100.
Gallerani, I., Innocenti, D. D., Coro-
nella, G., Berti, S., Amato, L.,
Moretti, S., et al. (2004). Cuta-
neous sarcoid-like granulomas in
a patient with X-linked hyper-IgM
syndrome. Pediatr. Dermatol. 21,
39–43.
Garchon, H. J., Luan, J. J., Eloy,
L., Bedossa, P., and Bach, J. F.
(1994). Genetic-analysis of immune
dysfunction in non-obese diabetic
(NOD) mice – mapping of a sus-
ceptibility locus close to the Bcl-2
gene correlates with increased resis-
tance of NOD T-cells to apopto-
sis induction. Eur. J. Immunol. 24,
380–384.
Gardet, A., and Xavier, R. J. (2012).
Common alleles that influence
autophagy and the risk for inflam-
matory bowel disease. Curr. Opin.
Immunol. 24, 522–529.
Geha, R. S., Notarangelo, L. D.,
Casanova, J. L., Chapel, H., Con-
ley, M. E., Fischer, A., et al.
(2007). Primary immunodeficiency
diseases: an update from the Inter-
national Union of Immunologi-
cal Societies Primary Immunodefi-
ciency Diseases Classification Com-
mittee. J. Allergy Clin. Immunol. 120,
776–794.
Gerke,V.,and Moss,S. E. (2002). Annex-
ins: from structure to function. Phys-
iol. Rev. 82, 331–371.
Gregoriou, S., Trimis, G., Charissi, C.,
Kalogeromitros, D., Stefanaki, K.,
and Rigopoulos, D. (2008). Cuta-
neous granulomas with predomi-
nantly CD8(+) lymphocytic infil-
trate in a child with severe combined
immunodeficiency. J. Cutan. Med.
Surg. 12, 246–248.
Gupta, D., Agarwal, R., Aggarwal, A. N.,
and Jindal, S. K. (2012). Sarcoido-
sis and tuberculosis: the same disease
with different manifestations or sim-
ilar manifestations of different dis-
orders. Curr. Opin. Pulm. Med. 18,
506–516.
Hofmann, S., Franke, A., Fischer, A.,
Jacobs, G., Nothnagel, M., Gaede,
K. I., et al. (2008). Genome-
wide association study identifies
ANXA11 as a new susceptibility
locus for sarcoidosis. Nat. Genet. 40,
1103–1106.
Holland, S. M. (2010). Chronic granu-
lomatous disease. Clin. Rev. Allergy
Immunol. 38, 3–10.
Hugot, J. P., Chamaillard, M., Zouali,
H., Lesage, S., Cezard, J. P.,
Belaiche, J., et al. (2001). Asso-
ciation of NOD2 leucine-rich
repeat variants with susceptibility
to Crohn’s disease. Nature 411,
599–603.
IJspeert, H., Lankester, A. C., van den
Berg, J. M., Wiegant, W., van Zelm,
M. C., et al. (2011). Artemis splice
defects cause atypical SCID and can
be restored in vitro by an antisense
oligonucleotide. Genes Immun. 12,
434–444.
Inoue, T., Boyle, D. L., Corr, M., Ham-
maker, D., Davis, R. J., Flavell, R.
A., et al. (2006). Mitogen-activated
protein kinase kinase 3 is a pivotal
pathway regulating p38 activation in
inflammatory arthritis. Proc. Natl.
Acad. Sci. U.S.A. 103, 5484–5489.
Intemann, C. D., Thye, T., Niemann, S.,
Browne, E. N. L., Chinbuah, M. A.,
Enimil, A., et al. (2009). Autophagy
gene variant IRGM-261T con-
tributes to protection from tubercu-
losis caused by Mycobacterium tuber-
culosis but not by M. africanum
strains. PLoS Pathog. 5:e1000577.
doi:10.1371/journal.ppat.1000577
Ishii, E., Matui, T., Iida, M., Inamitu,
T., and Ueda, K. (1987). Chediak-
Higashi-syndrome with intestinal
complication - report of a case. J.
Clin. Gastroenterol. 9, 556–558.
James, D. G. (2000). A clinicopatho-
logical classification of granuloma-
tous disorders. Postgrad. Med. J. 76,
457–465.
Janssen, C. E. I., Rose, C. D., De Hertogh,
G., Martin, T. M., Meunier, B. B.,
Cimaz,R., et al. (2012). Morphologic
and immunohistochemical charac-
terization of granulomas in the
nucleotide oligomerization domain
2-related disorders Blau syndrome
and Crohn disease. J. Allergy Clin.
Immunol. 129, 1076–1084.
Kobayashi, S. D., Voyich, J. M.,
Braughton, K. R., Whitney, A. R.,
Nauseef, W. M., Malech, H. L., et
al. (2004). Gene expression pro-
filing provides insight into the
pathophysiology of chronic granu-
lomatous disease. J. Immunol. 172,
636–643.
Kumar, D., Nath, L., Kamal, M. A.,
Varshney, A., Jain, A., Singh, S., et
al. (2010). Genome-wide analysis
of the host intracellular network
that regulates survival of Mycobac-
terium tuberculosis. Cell 140,
731–743.
Lawn, S. D., and Zumla, A. I. (2011).
Tuberculosis. Lancet 378, 57–72.
Lees, C. W., Barrett, J. C., Parkes,
M., and Satsangi, J. (2011). New
IBD genetics: common pathways
with other diseases. Gut 60,
1739–1753.
Levine, B., and Deretic, V. (2007).
Unveiling the roles of autophagy in
innate and adaptive immunity. Nat.
Rev. Immunol. 7, 767–777.
Levine, S., Smith, V. V., Malone, M., and
Sebire, N. J. (2005). Histopathologi-
cal features of chronic granuloma-
tous disease (CGD) in childhood.
Histopathology 47, 508–516.
Lockhart, E., Green, A. M., and Flynn,
J. L. (2006). IL-17 production is
dominated by gamma delta T cells
rather than CD4 T cells during
Mycobacterium tuberculosis infec-
tion. J. Immunol. 177, 4662–4669.
MacMicking, J. D., Taylor, G. A., and
McKinney, J. D. (2003). Immune
control of tuberculosis by IFN-
gamma-inducible LRG-47. Science
302, 654–659.
Marks, D. J. B., Harbord, M. W.
N., MacAllister, R., Rahman, F.
Z., Young, J., Al-Lazikani, B.,
et al. (2006). Defective acute
inflammation in Crohn’s disease: a
clinical investigation. Lancet 367,
668–678.
Marks,D. J. B.,Miyagi,K.,Rahman,F. Z.,
Novelli, M., Bloom, S. L., and Segal,
A. W. (2009). Inflammatory bowel
disease in CGD reproduces the clin-
icopathological features of Crohn’s
disease. Am. J. Gastroenterol. 104,
117–124.
Marks, D. J. B., and Segal, A. W. (2008).
Innate immunity in inflammatory
bowel disease: a disease hypothesis.
J. Pathol. 214, 260–266.
Martire, B., Rondelli, R., Soresina,
A., Pignata, C., Broccoletti, T.,
Finocchi, A., et al. (2008). Clin-
ical features, long-term follow-up
and outcome of a large cohort
of patients with chronic granulo-
matous disease: an Italian multi-
center study. Clin. Immunol. 126,
155–164.
Massara, A., Cavazzini, L., La Corte,
R., and Trotta, F. (2010). Sarcoidosis
appearing during anti-tumor necro-
sis factor alpha therapy: a new
“class effect” paradoxical phenome-
non. Two case reports and literature
review. Semin. Arthritis Rheum. 39,
313–319.
Mathew, S., Bauer, K. L., Fischoeder, A.,
Bhardwaj, N., and Oliver, S. J. (2008).
The anergic state in sarcoidosis is
associated with diminished den-
dritic cell function. J. Immunol. 181,
746–755.
Miller, E. A., and Ernst, J. D. (2009).
Anti-TNFα immunotherapy and
tuberculosis reactivation: another
mechanism revealed. J. Clin. Invest.
119, 1079–1082.
Moins-Teisserenc, H. T., Gadola, S. D.,
Cella, M., Dunbar, P. R., Exley,
A., Blake, N., et al. (1999). Asso-
ciation of a syndrome resembling
Wegener’s granulomatosis with low
surface expression of HLA class-I
molecules. Lancet 354, 1598–1603.
Ogura, Y., Bonen, D. K., Inohara, N.,
Nicolae, D. L., Chen, F. F., Ramos, R.,
et al. (2001). A frameshift mutation
in NOD2 associated with suscepti-
bility to Crohn’s disease. Nature 411,
603–606.
Pearce, E. J., Kane, C. M., Sun, J.,
Taylor, J. J., Mckee, A. S., and
Cervi, L. (2004). Th2 response polar-
ization during infection with the
helminth parasite Schistosoma man-
soni. Immunol. Rev. 201, 117–126.
Plantinga, T. S., Crisan, T. O., Oost-
ing, M., van de Veerdonk, F. L., de
Jong, D. J., Philpott, D. J., et al.
(2011). Crohn’s disease-associated
ATG16L1 polymorphism modu-
lates pro-inflammatory cytokine
responses selectively upon activation
of NOD2. Gut 60, 1229–1235.
Prescott, N. J., Fisher, S. A., Franke,
A., Hampe, J., Onnie, C. M., Soars,
D., et al. (2007). A nonsynonymous
SNP in ATG16L1 predisposes to ileal
Crohn’s disease and is independent
of CARD15 and 1BD5. Gastroen-
terology 132, 1665–1671.
Prior, C., Knight, R. A., Herold, M.,
Ott, G., and Spiteri, M. A. (1996).
Pulmonary sarcoidosis: patterns of
cytokine release in vitro. Eur. Respir.
J. 9, 47–53.
Rahman, F. Z., Hayee, B., Chee, R.,
Segal, A. W., and Smith, A. M.
(2009). Impaired macrophage func-
tion following bacterial stimulation
in chronic granulomatous disease.
Immunology 128, 253–259.
Rahman, F. Z., Marks, D. J. B., Hayee,
B. H., Smith, A. M., Bloom, S. L.,
and Segal, A. W. (2008). Phago-
cyte dysfunction and inflammatory
bowel disease. Inflamm. Bowel Dis.
14, 1443–1452.
Ramakrishnan, L. (2012). Revisiting the
role of the granuloma in tuberculo-
sis. Nat. Rev. Immunol. 12, 352–366.
Rao, R. V., Poksay, K. S., Castro-
Obregon, S., Schilling, B., Row, R.
H., del Rio, G., et al. (2004). Mol-
ecular components of a cell death
pathway activated by endoplasmic
reticulum stress. J. Biol. Chem. 279,
177–187.
Rastogi, R., Du, W. J., Ju, D. H., Pirock-
inaite, G., Liu, Y. S., Nunez, G., et
al. (2011). Dysregulation of p38 and
MKP-1 in response to NOD1/TLR4
Frontiers in Immunology | Inflammation May 2013 | Volume 4 | Article 120 | 10
Petersen and Smith innate immune system in granulomas
stimulation in sarcoid bronchoalve-
olar cells. Am. J. Respir. Crit. Care
Med. 183, 500–510.
Redford, P. S., Boonstra, A., Read, S.,
Pitt, J., Graham, C., Stavropoulos,
E., et al. (2010). Enhanced protec-
tion to Mycobacterium tuberculosis
infection in IL-10-deficient mice is
accompanied by early and enhanced
Th1 responses in the lung. Eur. J.
Immunol. 40, 2200–2210.
Reich, J. M. (2003). Adverse long-term
effect of corticosteroid therapy in
recent-onset sarcoidosis. Sarcoidosis
Vasc. Diffuse Lung Dis. 20, 227–234.
Reich, J. M. (2012). On the nature of
sarcoidosis. Eur. J. Intern. Med. 23,
105–109.
Rieber, N., Hector, A., Kuijpers, T.,
Roos, D., and Hartl, D. (2012). Cur-
rent concepts of hyperinflammation
in chronic granulomatous disease.
Clin. Dev. Immunol. 2012:252460.
doi: 10.1155/2012/252460.
Rose, C. D., Martin, T. M., and Wouters,
C. H. (2011). Blau syndrome revis-
ited. Curr. Opin. Rheumatol. 23,
411–418.
Savill, J., and Fadok, V. (2000). Corpse
clearance defines the meaning of cell
death. Nature 407, 784–788.
Schappi, M. G., Deffert, C., Fiette, L.,
Gavazzi, G., Herrmann, F. R., Belli,
D. C., et al. (2008). Branched fun-
gal beta-glucan causes hyperinflam-
mation and necrosis in phagocyte
NADPH oxidase-deficient mice. J.
Pathol. 214, 434–444.
Schinella, R. A., Greco, M. A., Cobert,
B. L., Denmark, L. W., and Cox, R.
P. (1980). Hermansky-Pudlak Syn-
drome with Granulomatous Colitis.
Ann. Intern. Med. 92, 20–23.
Schmid, D., Pypaert, M., and Munz, C.
(2007). Antigen-loading compart-
ments for major histocompatibility
complex class II molecules con-
tinuously receive input from
autophagosomes. Immunity 26,
79–92.
Schuetz, C., Huck, K., Gudowius, S.,
Megahed, M., Feyen, O., Hubner, B.,
et al. (2008). An immunodeficiency
disease with RAG mutations and
granulomas. N. Engl. J. Med. 358,
2030–2038.
Sebire, N. J., Haselden, S., Malone, M.,
Davies, E. G., and Ramsay, A. D.
(2003). Isolated EBV lymphopro-
liferative disease in a child with
Wiskott-Aldrich syndrome mani-
festing as cutaneous lymphomatoid
granulomatosis and responsive to
anti-CD20 immunotherapy. J. Clin.
Pathol. 56, 555–557.
Segal, A. W. (2005). How neutrophils
kill microbes. Annu. Rev. Immunol.
23, 197–223.
Segal, A. W., Webster, D., Jones, O. T. G.,
and Allison, A. C. (1978). Absence
of a newly described cytochrome-
B from neutrophils of patients
with chronic granulomatous disease.
Lancet 2, 446–449.
Sewell, G. W., Marks, D. J. B., and Segal,
A. W. (2009). The immunopatho-
genesis of Crohn’s disease: a three-
stage model. Curr. Opin. Immunol.
21, 506–513.
Smith, A. M., Rahman, F. Z., Hayee,
B., Graham, S. J., Marks, D. J.
B., Sewell, G. W., et al. (2009).
Disordered macrophage cytokine
secretion underlies impaired acute
inflammation and bacterial clear-
ance in Crohn’s disease. J. Exp. Med.
206, 1883–1897.
Sventoraityte, J., Zvirbliene, A., Franke,
A., Kwiatkowski, R., Kiudelis, G.,
Kupcinskas, L., et al. (2010). NOD2,
IL23R and ATG16L1 polymor-
phisms in Lithuanian patients with
inflammatory bowel disease. World
J. Gastroenterol. 16, 359–364.
Taylor, R. C., Cullen, S. P., and Mar-
tin, S. J. (2008). Apoptosis: con-
trolled demolition at the cellular
level. Nat. Rev. Mol. Cell Biol. 9,
231–241.
Torok, P., Glas, J., Endres, I., Tonenchi,
L., Teshome, M. Y., Wetzke, M., et al.
(2009). Epistasis between Toll-like
receptor-9 polymorphisms and vari-
ants in NOD2 and IL23R modulates
susceptibility to Crohn’s disease. Am.
J. Gastroenterol. 104, 1723–1733.
Travassos, L. H., Carneiro, L. A. M.,
Ramjeet, M., Hussey, S., Kim, Y.
G., Magalhaes, J. G., et al. (2010).
Nod1 and Nod2 direct autophagy by
recruiting ATG16L1 to the plasma
membrane at the site of bacterial
entry. Nat. Immunol. 11, 55–62.
Van Limbergen, J., Russell, R. K.,
Nimmo, E. R., Ho, G. T., Arnott,
I. D., Wilson, D. C., et al. (2007).
Genetics of the innate immune
response in inflammatory bowel
disease. Inflamm. Bowel Dis. 13,
338–355.
Volpp, B. D., Nauseef, W. M., and
Clark, R. A. (1988). Two cytosolic
neutrophil oxidase components
absent in autosomal chronic
granulomatous-disease. Science 242,
1295–1297.
Watt, F. E., James, O. F. W., and
Jones, D. E. J. (2004). Patterns of
autoimmunity in primary biliary
cirrhosis patients and their families:
a population-based cohort study.
QJM 97, 397–406.
Wehkamp, J., Salzman, N. H., Porter, E.,
Nuding, S., Weichenthal, M., Petras,
R. E., et al. (2005). Reduced Paneth
cell alpha-defensins in ileal Crohn’s
disease. Proc. Natl. Acad. Sci. U.S.A.
102, 18129–18134.
Wildenberg, M. E., Vos, A. C. W.,
Wolfkamp, S. C. S., Duijvestein, M.,
Verhaar, A. P., Te Velde, A. A., et
al. (2012). Autophagy attenuates the
adaptive immune response by desta-
bilizing the immunologic synapse.
Gastroenterology 142, 1493.
Winkelstein, J. A., Marino, M. C.,
Johnston, R. B., Boyle, J., Cur-
nutte, J., Gallin, J. I., et al. (2000).
Chronic granulomatous disease –
report on a national registry of 368
patients. Medicine (Baltimore) 79,
155–169.
Wolf, A. J., Linas, B., Trevejo-Nunez, G.
J., Kincaid, E., Tamura, T., Takatsu,
K., et al. (2007). Mycobacterium
tuberculosis infects dendritic cells
with high frequency and impairs
their function in vivo. J. Immunol.
179, 2509–2519.
Yasui, K., Yashiro, M., Tsuge, M.,
Manki, A., Takemoto, K., Yamamoto,
M., et al. (2010). Thalidomide
dramatically improves the symp-
toms of early-onset sarcoidosis/Blau
syndrome its possible action and
mechanism. Arthritis Rheum. 62,
250–257.
Yoo, J., Wolgamot, G., Torgerson, T.
R., and Sidbury, R. (2008). Cuta-
neous noncaseating granulomas
associated with Nijmegen breakage
syndrome. Arch. Dermatol. 144,
418–419.
Zimmer, J., Andres, E., Donato,
L., Hanau, D., Hentges, F., and
de la Salle, H. (2005). Clinical
and immunological aspects of
HLA class I deficiency. Qjm. 98,
719–727.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 30 January 2013; accepted: 05
May 2013; published online: 24 May
2013.
Citation: Petersen HJ and Smith
AM (2013) The role of the innate
immune system in granulomatous
disorders. Front. Immunol. 4:120. doi:
10.3389/fimmu.2013.00120
This article was submitted to Frontiers in
Inflammation, a specialty of Frontiers in
Immunology.
Copyright © 2013 Petersen and Smith.
This is an open-access article distributed
under the terms of the Creative Com-
mons Attribution License, which per-
mits use, distribution and reproduction
in other forums, provided the original
authors and source are credited and sub-
ject to any copyright notices concerning
any third-party graphics etc.
www.frontiersin.org May 2013 | Volume 4 | Article 120 | 11
